CKMTF: AI 评分 61/100 — AI 分析 (4月 2026)

Carmat S.A. is a French medical device company specializing in the design and development of a total artificial heart. Their innovative technology aims to provide a therapeutic alternative for patients suffering from end-stage biventricular heart failure.

Key Facts: AI Score: 61/100 Sector: Healthcare

公司概况

概要：

Carmat S.A., founded in 2008, focuses on developing and marketing the world's only total artificial heart, addressing a critical unmet need in end-stage heart failure. With a negative profit margin of -734.3%, the company is pre-profitability, relying on technological innovation and regulatory approvals for future growth in the medical devices sector.

CKMTF是做什么的？

Carmat S.A., established in 2008 and headquartered in Vélizy-Villacoublay, France, is a pioneering medical device company dedicated to creating a solution for patients with end-stage biventricular heart failure. The company's primary focus is the design, development, and eventual commercialization of a total artificial heart (TAH). This device is intended to provide a life-saving alternative for individuals who have exhausted all other medical and surgical options. Carmat's TAH is designed to mimic the function of a natural heart, providing both pulsatile flow and autoregulation, adapting to the patient's needs during rest and exercise. The company's geographic focus is currently in France and other international markets where it seeks regulatory approvals and partnerships for distribution. Carmat faces competition from established medical device companies that offer ventricular assist devices (VADs) and heart transplantation programs, but it differentiates itself with its total artificial heart technology, which aims to replace the entire failing heart.

CKMTF的投资论点是什么？

Carmat S.A. presents a high-risk, high-reward investment opportunity centered on its innovative total artificial heart (TAH). The company's value hinges on successful clinical trials, regulatory approvals, and eventual commercial adoption of its device. Key value drivers include expansion into new geographic markets and demonstration of long-term device efficacy and patient survival. Upcoming catalysts include ongoing clinical trial results and potential partnerships with larger medical device companies. The investment thesis is tempered by the company's current lack of profitability (P/E of -0.04 and a profit margin of -734.3%) and the inherent risks associated with medical device development and regulatory pathways. The company's beta of 1.38 indicates higher volatility than the overall market.

CKMTF在哪个行业运营？

Carmat S.A. operates within the medical device industry, specifically targeting the cardiovascular device segment. This segment is characterized by continuous innovation, driven by the need for more effective treatments for heart failure and other cardiovascular diseases. The market for heart failure devices is expected to grow as the aging population increases and the prevalence of heart disease rises. Carmat competes with companies offering ventricular assist devices (VADs) and heart transplantation programs. The company's total artificial heart represents a novel approach with the potential to capture a significant share of the market if it demonstrates superior clinical outcomes.

Medical Devices

Healthcare

CKMTF有哪些增长机遇？

Expansion into the United States market represents a significant growth opportunity for Carmat. Obtaining FDA approval for its total artificial heart would allow the company to access the large and lucrative U.S. market. This expansion would require successful completion of clinical trials in the U.S. and the establishment of a robust sales and marketing infrastructure. The timeline for this expansion is dependent on regulatory approval, but could potentially occur within the next 3-5 years.
Securing reimbursement agreements with healthcare providers and insurance companies is crucial for driving adoption of Carmat's total artificial heart. Positive clinical trial data demonstrating the cost-effectiveness of the device compared to existing treatments will be essential for negotiating favorable reimbursement terms. This process is ongoing and will likely continue over the next several years as the company gathers more data and expands its market presence.
Developing strategic partnerships with leading hospitals and cardiac centers can accelerate the adoption of Carmat's total artificial heart. These partnerships can provide access to key opinion leaders, facilitate clinical trials, and establish centers of excellence for training and device implantation. Building these relationships is an ongoing process that will be critical for the company's long-term success.
Expanding the indications for Carmat's total artificial heart to include a broader range of heart failure patients could significantly increase the addressable market. This would require further clinical trials to demonstrate the safety and efficacy of the device in different patient populations. This expansion could potentially occur within the next 5-7 years, depending on the results of ongoing research and development efforts.
Developing next-generation versions of its total artificial heart with improved features and functionality can help Carmat maintain its competitive edge. This could include enhancements to the device's biocompatibility, durability, and ease of implantation. Continuous innovation is essential for staying ahead of the competition and meeting the evolving needs of patients and clinicians. This is an ongoing process that will drive the company's long-term growth.

Carmat S.A. is focused on the development of a total artificial heart (TAH) addressing end-stage biventricular heart failure.
The company is headquartered in France and operates internationally, seeking regulatory approvals and partnerships.
Carmat's TAH is designed to mimic the function of a natural heart, providing pulsatile flow and autoregulation.
The company's market capitalization is $0.09 billion, reflecting its early stage and growth potential.
Carmat's profit margin is -734.3%, indicating significant ongoing investment in research and development.

CKMTF提供哪些产品和服务？

Designs and develops total artificial hearts.
Focuses on patients with end-stage biventricular heart failure.
Offers a therapeutic alternative to heart transplantation.
Develops devices that mimic the function of a natural heart.
Provides pulsatile blood flow and autoregulation.
Seeks regulatory approvals in France and internationally.

CKMTF如何赚钱？

Develops and manufactures total artificial hearts.
Seeks regulatory approvals for commercialization.
Partners with hospitals and cardiac centers for device implantation.
Generates revenue through sales of its artificial heart devices.

Patients with end-stage biventricular heart failure.
Hospitals and cardiac centers.
Cardiac surgeons.

Proprietary total artificial heart technology.
Patents protecting its device design and functionality.
First-mover advantage in the total artificial heart market.
Clinical data supporting the safety and efficacy of its device.

什么因素可能推动CKMTF股价上涨？

Upcoming: Results from ongoing clinical trials of Carmat's total artificial heart will provide crucial data on its safety and efficacy.
Upcoming: Potential regulatory approvals in new geographic markets, such as the United States, could significantly expand the company's market reach.
Ongoing: Development of strategic partnerships with leading hospitals and cardiac centers will facilitate the adoption of Carmat's technology.
Ongoing: Continued innovation and development of next-generation artificial heart technologies will maintain the company's competitive edge.
Ongoing: Positive media coverage and increased awareness of Carmat's technology can drive investor interest and market demand.

CKMTF的主要风险是什么？

Potential: Clinical trial failures or negative data could significantly impact the company's prospects.
Potential: Regulatory delays or rejections could delay or prevent the commercialization of Carmat's technology.
Ongoing: Competition from established medical device companies could limit Carmat's market share.
Ongoing: High development and manufacturing costs could strain the company's financial resources.
Ongoing: Limited reimbursement coverage from healthcare providers and insurance companies could hinder adoption of Carmat's technology.

CKMTF的核心优势是什么？

Innovative total artificial heart technology.
Potential to address a significant unmet medical need.
Strong intellectual property protection.
Experienced management team.

CKMTF的劣势是什么？

High development costs.
Regulatory hurdles.
Limited clinical data.
Lack of profitability.

CKMTF有哪些机遇？

Expansion into new geographic markets.
Development of new applications for its technology.
Strategic partnerships with leading hospitals.
Increasing awareness of heart failure and the need for advanced therapies.

CKMTF面临哪些威胁？

Competition from established medical device companies.
Technological obsolescence.
Changes in regulatory requirements.
Economic downturns.

CKMTF的竞争对手是谁？

Abbott Laboratories — Offers ventricular assist devices (VADs). — (ADOIF)
Asahi Kasei Corp — Develops and markets medical devices. — (AMEUF)
Edwards Lifesciences Corp — Focuses on heart valve technologies and hemodynamic monitoring. — (ETXPF)
Japan Medical Device — Unknown — (JMDMF)
Kiniksa Pharmaceuticals Ltd — Focuses on developing and commercializing therapeutic medicines. — (KIARF)

Key Metrics

MoonshotScore: 61/100

Company Profile

CEO: Stephane Piat
Headquarters: Vélizy-Villacoublay, FR
Employees: 182
Founded: 2018

AI Insight

AI analysis pending for CKMTF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Carmat S.A. do?

Carmat S.A. specializes in the development and manufacturing of a total artificial heart designed to address end-stage biventricular heart failure. Their device aims to provide a viable alternative for patients who are not eligible for or cannot receive a heart transplant. Carmat's technology mimics the natural heart's function, offering pulsatile blood flow and autoregulation to adapt to the patient's needs. The company is currently focused on securing regulatory approvals and establishing partnerships to commercialize its artificial heart in key markets.

What do analysts say about CKMTF stock?

As of 2026-03-15, there is no readily available analyst consensus on CKMTF due to its OTC listing and limited coverage. The company's valuation is influenced by factors such as clinical trial outcomes, regulatory approvals, and commercialization progress. Investors should carefully consider the risks and uncertainties associated with investing in a pre-profitability medical device company operating in a highly regulated industry. Key metrics to monitor include clinical trial results, regulatory milestones, and revenue growth following commercial launch.

What are the main risks for CKMTF?

Investing in Carmat S.A. (CKMTF) carries significant risks inherent to the medical device industry and its OTC listing. These risks include the potential for clinical trial failures, regulatory setbacks, and competition from established medical device companies. The company's lack of profitability and reliance on future funding also pose financial risks. Furthermore, the OTC listing exposes investors to liquidity risks and potential price volatility. Investors should carefully assess these risks and conduct thorough due diligence before investing in CKMTF.